Description
Anti-CD11a Antibody, Highly Galactosylated (BioBet-GA-056ZP) is a human IgG1 antibody against CD11a which contains with a high level of galactosylation.
Antibody Indication
Psoriasis
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD11a antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD11A
Full Name
CD11A
Background
ITGAL encodes the integrin alpha L chain. Integrins are heterodimeric integral membrane proteins composed of an alpha chain and a beta chain. This I-domain containing alpha integrin combines with the beta 2 chain (ITGB2) to form the integrin lymphocyte function-associated antigen-1 (LFA-1), which is expressed on all leukocytes. LFA-1 plays a central role in leukocyte intercellular adhesion through interactions with its ligands, ICAMs 1-3 (intercellular adhesion molecules 1 through 3), and also functions in lymphocyte costimulatory signaling. Involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes. Contributes to natural killer cell cytotoxicity.
Alternative Names
CD11A; LFA-1; ITGAL
Gene ID
3683
Cellular Localization
Plasma membrane
Genecards
6148
Involvement in Disease
Its related pathways are Integrin Pathway and Degradation of the extracellular matrix.
Related Pathways
Integrin ITGAL/ITGB2 is the receptor for ICAM1, ICAM2, ICAM3 and ICAM4. The integrin ITGAL/ITGB2 is the receptor for F11R (PubMed:11812992, PubMed:15528364). Integin ITGAL/ITGB2 is the receptor for the secreted ubiquitin-like protein ISG15; this interaction is mediated by ITGAL (PubMed: 29100055). Participate in a variety of immune phenomena, including leukocyte-endothelial cell interaction, cytotoxic T cell-mediated killing, and antibody-dependent killing of granulocytes and monocytes. Contribute to natural killer cell toxicity (PubMed: 15356110). Participate in the adhesion and transport of leukocytes including T cells and neutrophils (PubMed:11812992). There is a need to generate common lymphoid progenitor cells in the bone marrow, demonstrating its role in lymphogenesis (through similarity). The integrin ITGAL/ITGB2 is related to ICAM3 and contributes to the phagocytosis of macrophages and neutrophils (PubMed:23775590).
Field of research
In resting T-cells, up to 40% of surface ITGAL is constitutively phosphorylated. Phosphorylation causes conformational changes needed for ligand binding and is necessary for activation by some physiological agents.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
BioBet-GA-056ZP
Description
Efalizumab, sold under the trade name Raptiva, is a drug previously used to treat autoimmune diseases. Efalizumab binds to the CD11a subunit of lymphocyte function-associated antigen 1, and was originally used to treat psoriasis. .
Antibody Indication
Moderate to Severe Chronic Plaque Psoriasis
For the treatment of adult patients with moderate to severe chronic plaque psoriasis, these patients are suitable for phototherapy or systemic therapy.
